Details of the Drug Formulations

General Information of Drug (ID: DM5PFIJ)

• Drug Name: Givosiran Drug Info
• Synonyms: 1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280

Indication

Disease Entry	ICD 11	Status	REF
Acute intermittent hepatic porphyria	5C58.11	Approved	[1]

• Cross-matching ID:
  PubChem CID: 119058042
  CAS Number: 1639325-43-1
  TTD ID: DF36DY
  ACDINA ID: D01125

Full List of Drug Formulations Containing This Drug

Givosiran 189 mg/ml Injection

Company	Formulation ID	FDA Description
Alnylam Pharmaceuticals	F23181	Water

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019